Related Experiment Videos
Rational Vehicle Design Ensures Targeted Cutaneous Steroid Delivery
Leon Kircik1, Franklin Okumu2, Sateesh Kandavilli2
1Icahn School of Medicine at Mount Sinai, New York, New York.
The Journal of Clinical and Aesthetic Dermatology
|April 4, 2017
Summary
A new topical vehicle (Formulation-6/DFD-01) was developed to optimize betamethasone dipropionate skin retention and minimize systemic absorption. This formulation enhances corticosteroid delivery to skin layers for maximum efficacy and reduced side effects.
Area of Science:
- Dermatology
- Pharmaceutics
- Drug Delivery
Background:
- Topical corticosteroids like betamethasone dipropionate are crucial for treating inflammatory skin conditions.
- Optimizing drug delivery vehicles is essential to enhance therapeutic efficacy and minimize systemic side effects.
- Balancing skin penetration, retention, and systemic absorption remains a key challenge in topical formulation development.
Purpose of the Study:
- To design and evaluate a novel topical vehicle for betamethasone dipropionate (0.05%).
- To achieve an optimal balance between enhanced skin retention and minimal systemic absorption of the corticosteroid.
- To compare the performance of the designed vehicle against commercially available formulations.
Main Methods:
- Six test formulations incorporating betamethasone dipropionate with different alcohol penetration enhancers were prepared.
- Human cadaver skin was used in static Franz-cell diffusion systems to assess drug permeation over 24 hours.
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to quantify betamethasone in receptor fluid and skin layers (stratum corneum, epidermis, dermis).
Main Results:
- Formulation-6, utilizing oleyl alcohol, demonstrated the second-highest betamethasone retention in total skin with relatively low absorption into receptor fluid.
- The selected formulation, Formulation-6/DFD-01, exhibited superior skin retention and higher steroid levels in the epidermis and dermis compared to commercial products.
- Systemic absorption, indicated by receptor fluid levels, was minimized with Formulation-6/DFD-01, suggesting reduced potential for adverse effects.
Conclusions:
- Formulation-6/DFD-01 effectively balances betamethasone dipropionate retention within the skin layers.
- The designed vehicle maximizes local corticosteroid efficacy by ensuring prolonged presence in target tissues.
- Minimal systemic absorption of betamethasone dipropionate from Formulation-6/DFD-01 reduces the risk of hypothalamic-pituitary-adrenal axis suppression.